Fairmount Funds Management LLC bought ORKA

June 2, 2026 · Form 4 insider transaction

Fairmount Funds Management LLC bought 9,136 shares of Oruka Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.

Direction
Acquired (buy-side)
Shares
9,136
Price
$0.00
Total value
N/A
Role
SecurityStock Option (Right to Buy)
Transaction codeA: Grant or award
Transaction dateJune 2, 2026
Filing dateJune 3, 2026
Shares owned after9,136
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

This option represents a right to purchase 9,136 shares of the Issuer's common stock, which vests as to 1/12 of the option monthly from June 2, 2026, subject to the recipient's continued service to the Issuer.; Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II LP ("Fund II") and Fairmount Healthcare Co-Invest III L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

View the original Form 4 on SEC EDGAR